<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>FRAGMENTA: End-to-end Fragmentation-based Generative Model with Agentic Tuning for Drug Lead Optimization - Health AI Hub</title>
    <meta name="description" content="FRAGMENTA is an end-to-end generative AI framework designed to overcome challenges in drug lead optimization, particularly with limited training data, by integr">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>FRAGMENTA: End-to-end Fragmentation-based Generative Model with Agentic Tuning for Drug Lead Optimization</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.20510v2" target="_blank">2511.20510v2</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-25
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Yuto Suzuki, Paul Awolade, Daniel V. LaBarbera, Farnoush Banaei-Kashani
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.AI
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.20510v2" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.20510v2" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">FRAGMENTA is an end-to-end generative AI framework designed to overcome challenges in drug lead optimization, particularly with limited training data, by integrating a novel fragmentation-based generative model with an agentic AI tuning system. It reframes fragmentation as a 'vocabulary selection' problem optimized via dynamic Q-learning, and employs conversational AI to learn from domain experts, automating objective refinement. In real-world cancer drug discovery, FRAGMENTA significantly outperformed baselines, with its autonomous Agent-Agent system surpassing traditional human-human tuning.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This technology significantly accelerates and optimizes the drug discovery process, particularly for identifying drug lead candidates, which can lead to faster development of new, more effective therapies for patients, especially in areas with high unmet needs like cancer.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The paper describes the application of generative AI and agentic AI systems to automate and optimize the process of identifying promising drug lead molecules. This involves reframing fragmentation as a 'vocabulary selection' problem and using dynamic Q-learning for joint optimization, along with an agentic AI system for refining objectives via conversational feedback from domain experts (e.g., medicinal chemists). The goal is to accelerate the discovery of new drugs for diseases like cancer.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses the critical problem of molecule generation for drug discovery when class-specific datasets are extremely small, often fewer than 100 training examples.</li>
                    
                    <li>Introduces a novel generative model that reimagines molecule fragmentation as a 'vocabulary selection' problem, employing dynamic Q-learning to jointly optimize both fragmentation and molecule generation.</li>
                    
                    <li>Develops an agentic AI system that refines drug lead optimization objectives through direct conversational feedback from domain experts (e.g., medicinal chemists), thereby removing the AI engineer from the tuning loop.</li>
                    
                    <li>The agentic system progressively learns and accumulates domain knowledge, aiming to eventually automate the entire model tuning process.</li>
                    
                    <li>In real-world cancer drug discovery experiments, FRAGMENTA's 'Human-Agent' configuration identified nearly twice as many high-scoring molecules compared to existing baseline methods.</li>
                    
                    <li>The fully autonomous 'Agent-Agent' system demonstrated superior performance to traditional 'Human-Human' tuning in capturing and acting upon expert intent.</li>
                    
                    <li>FRAGMENTA aims to overcome the limitations of conventional heuristic fragmentation, which often restrict molecular diversity and miss crucial fragments, by dynamically optimizing fragmentation.</li>
                    
                    <li>The framework's end-to-end nature signifies a comprehensive solution from initial fragmentation strategy to final lead optimization.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>FRAGMENTA uses a two-component framework: 1) A novel generative model based on dynamic Q-learning that optimizes molecule fragmentation (viewed as 'vocabulary selection') and molecule generation concurrently. 2) An agentic AI system that iteratively refines optimization objectives through conversational feedback from domain experts, progressively learning domain knowledge to automate model tuning.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>FRAGMENTA's Human-Agent configuration identified nearly twice as many high-scoring molecules in cancer drug discovery experiments compared to baselines. Furthermore, the fully autonomous Agent-Agent system outperformed traditional Human-Human tuning, demonstrating effective capture of expert intent and superior lead optimization.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This approach has the potential to dramatically shorten the preclinical drug discovery phase by more efficiently generating and optimizing potential drug candidates. This could lead to a faster pipeline of novel therapeutics entering clinical trials, offering new treatment options for diseases like cancer. The automation of tuning also reduces reliance on direct human collaboration, making the process more scalable and less prone to bottlenecks.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>Not explicitly mentioned in the abstract.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>Not explicitly mentioned in the abstract.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Pharmacology</span>
                    
                    <span class="tag">Medicinal Chemistry</span>
                    
                    <span class="tag">Drug Development</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">generative AI</span>
                    
                    <span class="tag tag-keyword">drug discovery</span>
                    
                    <span class="tag tag-keyword">molecule generation</span>
                    
                    <span class="tag tag-keyword">fragmentation</span>
                    
                    <span class="tag tag-keyword">Q-learning</span>
                    
                    <span class="tag tag-keyword">agentic AI</span>
                    
                    <span class="tag tag-keyword">drug lead optimization</span>
                    
                    <span class="tag tag-keyword">cancer therapeutics</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Molecule generation using generative AI is vital for drug discovery, yet class-specific datasets often contain fewer than 100 training examples. While fragment-based models handle limited data better than atom-based approaches, existing heuristic fragmentation limits diversity and misses key fragments. Additionally, model tuning typically requires slow, indirect collaboration between medicinal chemists and AI engineers. We introduce FRAGMENTA, an end-to-end framework for drug lead optimization comprising: 1) a novel generative model that reframes fragmentation as a "vocabulary selection" problem, using dynamic Q-learning to jointly optimize fragmentation and generation; and 2) an agentic AI system that refines objectives via conversational feedback from domain experts. This system removes the AI engineer from the loop and progressively learns domain knowledge to eventually automate tuning. In real-world cancer drug discovery experiments, FRAGMENTA's Human-Agent configuration identified nearly twice as many high-scoring molecules as baselines. Furthermore, the fully autonomous Agent-Agent system outperformed traditional Human-Human tuning, demonstrating the efficacy of agentic tuning in capturing expert intent.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>